Pre-Conference
Workshop I: Introduction to Drug
Administration
Dr. Guozhong Rui, Director, Chinese Research and
Commercialization Center for Medicinal Technology
Dr. Andrew Chang, Associate Director for
Policy and Regulation, Division of Hematology , OBRR,
CBER, FDA, USA
Dr. Emily Shacter, Chief, Laboratory of
Biochemistry, Division of Therapeutic Proteins, Office of Biotechnology
Products, Center for Drug Evaluation and Research, FDA, USA
Workshop II: International
Venture Capital Training
Part I: How Multi-national Companies
Protect and Leverage Intellectual Property Rights
Mr.
Kening Li,Crowell & Moring, LLP, USA
Part II: How Universities/non-profit
Research Organizations and Small Start-up Companies Protect and Leverage Intellectual
Property Rights
The Speakers are Under
Organizing!
Part III Introduction to U.S.
Food and Drug Law and Regulations
The Speakers are Under
Organizing!
Part IV Introduction to Practices
in Front of the U.S. International Trade Commission (ITC) and Investigations
The Speakers are Under
Organizing!
Keynote speech
Title: RNase P and the
Inhibition of Gene Expression in Human Cells
Dr. Sidney Altman, Nobel Prize laureates in Chemistry 1989
Title: Defining Innovation in
21st Century Medicine
Dr. Lee Babiss, Vice President, Preclinical Research and Development.
Hoffmann-La, Roche, Inc. USA
Session
1: Anti-Cardiovascular Diseases Drug Discovery & Development
Title: Nitric Oxide Donors Protect Myocardium Against Infarction
Dr. Guang-Wu Wang, Assistant Research Cardiologist, UCLA School
of Medicine
Title: (TBD)
Dr. Emery H. Bresnick, Professor of Pharmacology, University of
Wisconsin-Madison, USA
Title: Pharmacogenomic and Pharmacoproteomic
for Cardiovascular Drugs
Dr.
Gvard Siest, Professor, Centre du Muicament, France
Session
2: Latest Advances in New Drug Discovery of Liver Diseases
Title: New
Developments in Hepatitis C treatment
Dr. Bhupinder S. Anand, Professor, Baylor College of Medicine &
Michael E. DeBakey VA Medical Center, Houston, Texas, USA
Title: Pharmacogenetics of Drug Metabolism Enzymes in
Relation to Drug Toxicity and Disease Susceptibility Factors.
Dr. Glyn Steventon, Professor, King's College London, UK
Title: New Drug Discovery in Viral Models Herpes Simplex
Viruses
Dr. Luis M Schang, Department of Biochemistry and Department
of Molecular Microbiology and Immunology, Signal Transduction Research Group, University
of Alberta, Canada
Title: Current Status of Antivirals for HBV and Novel
Approaches Based on HBV-Host Interactions
Dr. William Chen Wei Ning, Associate Professor, Division of Chemical
and Biomolecular Engineering, School of Chemical and Biomedical Engineering,
College of Engineering, Nanyang Technological University, Singapore
Session 3: New Drug Discovery &
Development in HIV & Serious Epidemic Infectious Diseases
Title: (TBD)
Dr. Genfa Zhou, President, Fusogen Pharmaceuticals, Inc.,
Tianjin, China
Title: (TBD)
Dr. Ian Woolley, Professor, Department of Infectious Disease
and Clinical Epidemiology, Monash Medicine Centre, USA
Title: Blocking Viral Entry: A Complementary Strategy
for HIV Therapy
Dr. Shibo Jiang, Head of Viral Immunology Laboratory, New
York Blood Center, USA
Title: (TBD)
Dr. Stuart Le Grice, Chief, Resistance
Mechanisms Laboratory and Chief, RT Biochemistry Section, HIV Drug Resistance Program,
National Cancer Institute, USA
Title: Novel patented HIV protease inhibitors which
act as inhibitors of Pglycoprotein
Dr. Andreas Hilgeroth, PD, Co-Editor von
Medicinal Chemistry, Martin-Luther-University
Halle-Wittenberg, Germany
Title: Anti-HIV drug and their prodrugs
Dr. Marina Kukhanova, Engelhardt Institute of Molecular Biology, Russia
Session 4: New Drug Development of Cancer
/Tumors and Leukaemia
Title: (TBD)
Dr. Bin Liu, Assistant Professor, Department of
Anesthesia, UCSF Comprehensive Cancer Center, USA
Title: (TBD)
Dr.
Bozena Kaminska, Department of Cell Biology, Laboratory of Transcription
Regulation, Nencki Institute of Experimental Biology, Poland
Title: Cyclooxygenase-1
and Bicistronic Cyclooxygenase-1/Prostacyclin Synthase Gene Transfer Protect
Against Ischemic Cerebral Infarction
Dr. Kenneth K. Wu, Associate Director, Center for Vascular
Biology, The Brown Foundation Institute of Molecular Medicine, USA
Title: (TBD)
Dr. Yong
Jia, Department of Molecular Pharmacology, Abbott Bioresearch Center,
Worcester, USA
Title: Screening and Preclinical
Study of Anticancer Drugs
Dr.
Weimin Fan, Professor of Pathology and Medicine, Member, Hollings Cancer Center, Medical
University of South Carolina, USA
Title: Molecular Pncology and
Targeted Cancer Therapy
Dr.
Weikang Tao, Department of Cancer Research, Merck Research Laboratories, USA
Session
5: Anti-Diabetes and Anti-Metabolic Disorder Drug Discovery & Development
Session Chair: Dr.
William Cho, Scientific
Officer, Queen Elizabeth Hospital, Hong Kong, China
Title: Practice in Family Medicine and Diabetes
Epidemiology and Biological Markers in Diabetes and Its Complications.
Dr. Deyi Zheng, Palmetto Health
Richland Hospital/USC SOM
Title: Modulation of Mitochondrial Structure and
Function and Mitochondrial Stress Signaling in Diabetes
Dr. Narayan G. Avadhani, Professor, University of Pennsylvania, USA
Title: (TBD)
Dr. Chun-Cheng Lin, Associate Research Fellow, Institute of
Chemistry, Academia Sinica, Taiwan, China
Title: Proteomic and Medicinal Approaches to Diabetes
and Its Complications
Dr. William Cho, Scientific Officer, Queen Elizabeth
Hospital, Hong Kong, China
Title: (TBD)
Dr. James R. Gavin, Professor, Clinical Professor of Medicine
Emory University of Medicine, Executive Vice President for Clinical Affairs,
Healing Our Village, Inc., USA
Session 6: Drug Discovery of Alzheimer's Disease (AD),
Parkinson's Disease (PD)and Related Aging Disorders
Title: Novel
Multifunctional Neuroprotective-Neurorescue Anti-Alzheimer,
Anti-Parkinson Drugs with Various Cns Targets
Dr. Moussa . B. H. Youdim, National Parkinson Foundation (US) Centers
of Excellence for Neurodegenerative Diseases Technion-Faculty of Medicine
Haifa, Israel
Title: New
potential treatments (eg. Anti-oxidants and omega 3 polyunsaturated fatty
acids) against Alzheimer’s disease and other aging related didorders, from an
epidemiological point of view.
Dr. Pascale Barberger –
Gateau, Epidemiology,
Public Health and Development, French
Title: The Investigation of Potential Biomarkers for the
Diagnosis of Alzheimer's Disease in Human Cerebrospinal Fluid.
Dr. Alex E. Roher, Director, Sun Health Research Institute,
USA
Title: Synthesis and Development of Potent and
Selective mGluR2/3 Agonists
Dr. Lushi Tan, Merck & Co., Inc., USA
Title: Developing
Neuropsychiatric Research and Services in China
Dr. Roger Bullock, Kingshill Research
Centre, Victoria Hospital, Swindon UK
Title:
Drug Treatment in Alzheimer's Disease
Dr. Esther Ebeneezer, University Hospital Kuala Lumpu
Session 7: Master Medicinal Chemistry to Develop More
Potent, Safe and New Anti-Major Disease Medicines
Title: Glucokinase Activators
Dr. Ramakanth Sarabu, Hoffmann-La Roche, USA
Title: Involved in the Identification of the Dasatinib
(BMS-354825) as a Dual Src/Abl Kinase Inhibitor
Dr. Ping Chen, Bristol-Myers Squibb, USA
Title: (TBD)
Dr. K V Sashidhara, Scientist, Central Drug
Research Institute Medicinal, India
Title: Structure-Activity
Relationship of β-MSH Derived Melanocortin-4 Receptor Agonists
and Its Potential Use as an Anti-obesity Agent
Dr. Liang Z. Yan, Lilly Research
Laboratories, A Division of Eli Lilly & Co., Lilly Corporate Center, USA
Title: Studies on
Nitric Oxide-donating Drugs
Dr. Yihua Zhang, Drug Discovery Center, China Pharmaceutical University
Session
8: Globalization, Standardization and Modernization of TCM
Title: Innovation Drug R&D Based on the
Traditional Chinese Herbs
Dr. Ke Liu, CEO, Research Institute of Luye
Pharmaceutical (RILP), China
Title: (TBD)
Dr. Weishuo Fang, Associate Dean, Chinese Academy of Medical
Science & Peking Union Medical College
Title: (TBD)
Dr. Shide Luo, Institute of Kunming Botany, Chinese
Academy of Science, China
Biopharmaceutical Company Venture Capital Forum
Title: Venture Capital Investors'
Perspective on Biotechnology.
Mr.
Kening Li,Crowell & Moring, LLP, USA
Title: (TBD)
Mr. David Zhang, Executive
Vice President, THE WI HARPOR
Group, USA
Title: (TBD)
Mr. M C Tang, Chairman, MBA, Chairman, World Tech
Ventures and TAGC Bio-Ventures, USA
Title: (TBD)
Mr. Tianping Wu, President,
HK Wonderful Investment Group,
ShangHai branch, China
